4.5 Article

Hemizygous deletions on chromosome 1p21.3 involving the DPYD gene in individuals with autism spectrum disorder

期刊

CLINICAL GENETICS
卷 80, 期 5, 页码 435-443

出版社

WILEY
DOI: 10.1111/j.1399-0004.2010.01578.x

关键词

autism; copy number variants; dihydropyrimidine dehydrogenase; DPYD; microarray; PTCHD1

资金

  1. Centre for Applied Genomics (TCAG), Genome Canada/Ontario Genomics Institute
  2. Canadian Institutes of Health Research (CIHR)
  3. McLaughlin Centre
  4. Canadian Institute of Advanced Research
  5. Hospital for Sick Children (SickKids) Foundation
  6. Autism Research Training (ART) Program

向作者/读者索取更多资源

We describe the identification and clinical presentation of four individuals from three unrelated families with hemizygous deletions involving the DPYD gene at chromosome 1p21.3. DPYD encodes dihydropyrimidine dehydrogenase, which is the initial and rate-limiting enzyme in the catabolism of pyrimidine bases. All four individuals described met diagnostic criteria for autism spectrum disorder with severe speech delay. Patient 1's deletion was originally reported in 2008, and more detailed clinical information is provided. Subsequently, this male individual was found to have a missense mutation in the X-linked PTCHD1 autism susceptibility gene, which may also contribute to the phenotype. Patients 2 and 3 are siblings with a novel deletion encompassing the DPYD gene. In their mother, the genomic region deleted from chromosome 1p21.3 was inserted into chromosome 10. A fourth proband had a novel 10-kb intragenic deletion of exon 6 of the DPYD gene detected on a higher resolution microarray. Our study suggests that hemizygous deletions involving the DPYD locus present with variable phenotypes which can include speech delay and autistic features, and may also be influenced by additional mutations in other genes, issues which need to be considered in genetic counseling.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据